11
total announcements
JAGSNPHARM.NS · 15 min delayed
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has scheduled a conference call with analysts and investors on July 30, 2026, to discuss its Q1 FY27 financial results.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the allotment of 94,000 equity shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022) to eligible employees.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals has completed the acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited, as per its proposed acquisition of 85% stake.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the completion of acquisition of 69.77% stake in Aequitas Healthcare Private Limited, making Aequitas a subsidiary of Jagsonpal.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited will remain closed for Designated Persons and their immediate relative(s) from July 01, 2026, and will open 48 hours after the declaration of unaudited financial results for the quarter ended on June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director on its Board, bringing over three decades of experience in the pharmaceutical and healthcare sectors.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about the appointment of Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mr. Anil Kumar Matai as a Non-Executive Independent Director of the company, effective June 25, 2026.